Literature DB >> 16034108

CD8+ T cell tolerance in nonobese diabetic mice is restored by insulin-dependent diabetes resistance alleles.

Xavier Martinez1, Huub T C Kreuwel, William L Redmond, Rebecca Trenney, Kara Hunter, Hugh Rosen, Nora Sarvetnick, Linda S Wicker, Linda A Sherman.   

Abstract

Although candidate genes controlling autoimmune disease can now be identified, a major challenge that remains is defining the resulting cellular events mediated by each locus. In the current study we have used NOD-InsHA transgenic mice that express the influenza hemagglutinin (HA) as an islet Ag to compare the fate of HA-specific CD8+ T cells in diabetes susceptible NOD-InsHA mice with that observed in diabetes-resistant congenic mice having protective alleles at insulin-dependent diabetes (Idd) 3, Idd5.1, and Idd5.2 (Idd3/5 strain) or at Idd9.1, Idd9.2, and Idd9.3 (Idd9 strain). We demonstrate that protection from diabetes in each case is correlated with functional tolerance of endogenous islet-specific CD8+ T cells. However, by following the fate of naive, CFSE-labeled, islet Ag-specific CD8+ (HA-specific clone-4) or CD4+ (BDC2.5) T cells, we observed that tolerance is achieved differently in each protected strain. In Idd3/5 mice, tolerance occurs during the initial activation of islet Ag-specific CD8+ and CD4+ T cells in the pancreatic lymph nodes where CD25+ regulatory T cells (Tregs) effectively prevent their accumulation. In contrast, resistance alleles in Idd9 mice do not prevent the accumulation of islet Ag-specific CD8+ and CD4+ T cells in the pancreatic lymph nodes, indicating that tolerance occurs at a later checkpoint. These results underscore the variety of ways that autoimmunity can be prevented and identify the elimination of islet-specific CD8+ T cells as a common indicator of high-level protection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16034108     DOI: 10.4049/jimmunol.175.3.1677

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  CD11a/ICAM-1 blockade combined with IL-2 targeting therapy causes a paradoxical acceleration of type 1 diabetes.

Authors:  Ekua W Brenu; Timothy J Bartley; Casey M Wright; Emma E Hamilton-Williams
Journal:  Immunol Cell Biol       Date:  2017-06-14       Impact factor: 5.126

2.  Cutting edge: type 1 diabetes occurs despite robust anergy among endogenous insulin-specific CD4 T cells in NOD mice.

Authors:  Kristen E Pauken; Jonathan L Linehan; Justin A Spanier; Nathanael L Sahli; Lokesh A Kalekar; Bryce A Binstadt; James J Moon; Daniel L Mueller; Marc K Jenkins; Brian T Fife
Journal:  J Immunol       Date:  2013-10-11       Impact factor: 5.422

3.  Cetuximab-mediated tumor regression depends on innate and adaptive immune responses.

Authors:  Xuanming Yang; Xunmin Zhang; Eric D Mortenson; Olga Radkevich-Brown; Yang Wang; Yang-Xin Fu
Journal:  Mol Ther       Date:  2012-09-18       Impact factor: 11.454

4.  Genetic interactions among Idd3, Idd5.1, Idd5.2, and Idd5.3 protective loci in the nonobese diabetic mouse model of type 1 diabetes.

Authors:  Xiaotian Lin; Emma E Hamilton-Williams; Daniel B Rainbow; Kara M Hunter; Yang D Dai; Jocelyn Cheung; Laurence B Peterson; Linda S Wicker; Linda A Sherman
Journal:  J Immunol       Date:  2013-02-20       Impact factor: 5.422

5.  Idd9.2 and Idd9.3 protective alleles function in CD4+ T-cells and nonlymphoid cells to prevent expansion of pathogenic islet-specific CD8+ T-cells.

Authors:  Emma E Hamilton-Williams; S B Justin Wong; Xavier Martinez; Daniel B Rainbow; Kara M Hunter; Linda S Wicker; Linda A Sherman
Journal:  Diabetes       Date:  2010-03-18       Impact factor: 9.461

6.  The IL-2/CD25 pathway determines susceptibility to T1D in humans and NOD mice.

Authors:  Calliope A Dendrou; Linda S Wicker
Journal:  J Clin Immunol       Date:  2008-09-09       Impact factor: 8.317

7.  Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells.

Authors:  Joseph F Grosso; Monica V Goldberg; Derese Getnet; Tullia C Bruno; Hung-Rong Yen; Kristin J Pyle; Edward Hipkiss; Dario A A Vignali; Drew M Pardoll; Charles G Drake
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

8.  Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy.

Authors:  Grégory Verdeil; Kristi Marquardt; Charles D Surh; Linda A Sherman
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-20       Impact factor: 11.205

9.  Drak2 regulates the survival of activated T cells and is required for organ-specific autoimmune disease.

Authors:  Maureen A McGargill; Carmen Choy; Ben G Wen; Stephen M Hedrick
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

10.  Idd9.1 locus controls the suppressive activity of FoxP3+CD4+CD25+ regulatory T-cells.

Authors:  Jun Yamanouchi; Maria-Carmen Puertas; Joan Verdaguer; Paul A Lyons; Daniel B Rainbow; Giselle Chamberlain; Kara M Hunter; Laurence B Peterson; Linda S Wicker; Pere Santamaria
Journal:  Diabetes       Date:  2009-10-15       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.